Clinical trial
An Open-Label, Randomised, Multi-Centre, Phase II Study to Investigate the Safety and Efficacy of AT13387, Either as Monotherapy or in Combination With Imatinib, in Patients With Unresectable and/or Metastatic Malignant GIST Whose Tumour Has Progressed Following Treatment With a Maximum of Three Tyrosine Kinase Inhibitors
NCT01294202 is registered in ClinicalTrials.gov with Astex Pharmaceuticals, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-Label, Randomised, Multi-Centre, Phase II Study to Investigate the Safety and Efficacy of AT13387, Either as Monotherapy or in Combination With Imatinib, in Patients With Unresectable and/or Metastatic Malignant GIST Whose Tumour Has Progressed Following Treatment With a Maximum of Three Tyrosine Kinase Inhibitors
- Lead sponsor
- Astex Pharmaceuticals, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- March 31, 2011
- Completion date
- July 31, 2014
- Enrollment
- 26 (actual)
- Sites
- 8
Conditions
As the registry lists them; a condition with its own page is linked.
gastrointestinal stromal tumor (gist)